Exact Sciences partners with Norweigian firm
Exact Sciences Corp. said today it has entered into an agreement with a Norwegian company that seeks to commercialize its colorectal cancer screening technologies outside the United States and Canada.
The collaboration and nonexclusive license agreement is with NorDiag ASA, said Exact Sciences, which is headquartered in Marlborough.
"This agreement fulfills one of our key corporate goals, which is to expand our DNA-based colorectal cancer screening technologies into international markets where there is a tremendous need for new methods," Exact Sciences chief executive Don Hardison said in a statement.
(By Chris Reidy, Globe staff)